Jurickson Profar faces a 162-game suspension for performance-enhancing drugs after his appeal was denied, marking the end of his 2026 season with the Atlanta Braves. The decision comes as Major League Baseball confirmed Profar tested positive for exogenous testosterone and its metabolites, resulting in the full-season ban for a second violation. The suspension makes him the sixth player to receive such a penalty since MLB implemented the policy in 2014, which mandates a 162-game suspension for repeat offenders. Profar, 33, will forfeit his $15 million salary for 2026 and will be ineligible for postseason play. The suspension follows a prior 80-game ban in March 2025 after he tested positive for chorionic gonadotropin (hCG), a hormone linked to testosterone production. At the time, Profar issued a statement acknowledging his responsibility and accepting MLB’s decision, though he denied intentional wrongdoing. His 2025 suspension came early in the season, and after returning in July, he posted a .245/.353/.434 batting line with 14 home runs and 43 RBIs while playing left field. The Braves signed Profar to a three-year, $42 million contract in January 2025 after he had a standout season with the San Diego Padres. As an All-Star in 2024, Profar was expected to play a key role in Atlanta’s lineup, potentially as the No. 2 hitter behind Ronald Acuña Jr. However, his absence for the entire 2026 season will reshape the team’s plans. Braves first-year manager Walt Weiss noted the DH position will be “fairly fluid” without Profar, citing the addition of left fielder Mike Yastrzemski, who signed a $23 million, two-year deal in the offseason. Yastrzemski, along with Acuña and Michael Harris, is expected to form the starting outfield.#atlanta_braves #jurickson_profar #major_league_baseball #walt_weiss #mike_yastrzemski
